{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:16Z","timestamp":1788922156470,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5UG3DA048775-02"],"award-info":[{"award-number":["5UG3DA048775-02"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31 DA059235"],"award-info":[{"award-number":["F31 DA059235"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014234","name":"Molecular Engineering and Sciences Institute, University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009037","name":"Clean Energy Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["NNCI-2025489"],"award-info":[{"award-number":["NNCI-2025489"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["NNCI-1542101"],"award-info":[{"award-number":["NNCI-1542101"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114294","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:33:09Z","timestamp":1759797189000},"page":"114294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P1","title":["Innate immune mechanisms underlying the efficacy of a next-generation nanoparticle-based vaccine against opioid use disorders"],"prefix":"10.1016","volume":"388","author":[{"given":"Fatima A.","family":"Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobra","family":"Rostamizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Skiados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyet-Minh Nguyen","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Marecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Luengas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114294_bb0005","first-page":"70","article-title":"State-level economic costs of opioid use disorder and fatal opioid overdose \u2014 United States, 2017","author":"Luo","year":"2021","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.jconrel.2025.114294_bb0015","author":"CDC"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"15","key":"10.1016\/j.jconrel.2025.114294_bb0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jconrel.2025.114294_bb0030","article-title":"FDA approval summary: nalmefene nasal spray for the emergency treatment of known or suspected opioid overdose","author":"Nallani","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114294_bb0035","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114294_bb0040","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacotherapies for treating opioid use disorder","volume":"39","author":"Banks","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/acschembio.1c00026","article-title":"A highly efficacious Carfentanil vaccine that blunts opioid-induced Antinociception and respiratory depression","volume":"16","author":"Eubanks","year":"2021","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41541-023-00697-9","article-title":"A TLR7\/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models","volume":"8","author":"Crouse","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"23","key":"10.1016\/j.jconrel.2025.114294_bb0060","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/acsptsci.3c00228","article-title":"Multivalent vaccination strategies protect against exposure to polydrug opioid and stimulant mixtures in mice and rats","volume":"7","author":"Song","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2025.114294_bb0070","first-page":"8","article-title":"Nicotine vaccines for smoking cessation","author":"Hartmann-Boyce","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114294_bb0075","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114294_bb0080","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol. Rev."},{"issue":"23","key":"10.1016\/j.jconrel.2025.114294_bb0085","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jconrel.2025.114294_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/acsptsci.1c00260","article-title":"Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to Carfentanil, fentanyl, and their mixtures in rats","volume":"5","author":"Crouse","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"26","key":"10.1016\/j.jconrel.2025.114294_bb0100","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.vaccine.2013.04.027","article-title":"Liposomes containing monophosphoryl lipid a: a potent adjuvant system for inducing antibodies to heroin hapten analogs","volume":"31","author":"Matyas","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114294_bb0105","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0110","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1038\/s41598-018-23777-6","article-title":"Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose","volume":"8","author":"Laudenbach","year":"2018","journal-title":"Sci. Rep."},{"issue":"30","key":"10.1016\/j.jconrel.2025.114294_bb0115","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1016\/j.vaccine.2020.05.027","article-title":"Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity","volume":"38","author":"Gradinati","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jconrel.2025.114294_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096547","article-title":"Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.114294_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119744","article-title":"Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: a perspective","volume":"280","author":"Chan","year":"2021","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114294_bb0130","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/acsbiomaterials.0c01496","article-title":"Prolonged Codelivery of hemagglutinin and a TLR7\/8 agonist in a supramolecular polymer-nanoparticle hydrogel enhances potency and breadth of influenza vaccination","volume":"7","author":"Roth","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114294_bb0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.rvsc.2014.03.002","article-title":"Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice","volume":"96","author":"Mansoor","year":"2014","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.jconrel.2025.114294_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114294_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.biomaterials.2016.08.028","article-title":"The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine","volume":"106","author":"Hu","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114294_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.biomaterials.2017.01.038","article-title":"Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: a focus on hapten density","volume":"123","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114294_bb0160","article-title":"A cationic liposome-formulated Toll Like Receptor (TLR)7\/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity","author":"Hamid","year":"2025","journal-title":"bioRxiv"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114294_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202419031","article-title":"A fentanyl Hapten-displaying lipid nanoparticle vaccine that non-covalently encapsulates a TLR7\/8 agonist and T-helper epitope induces protective anti-fentanyl immunity","volume":"64","author":"Zhong","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114294_bb0170","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.114294_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103699","article-title":"Current and future nanoparticle vaccines for COVID-19","volume":"74","author":"Vu","year":"2021","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114294_bb0180","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1039\/c2nr32880a","article-title":"Lipid-enveloped hybrid nanoparticles for drug delivery","volume":"5","author":"Tan","year":"2013","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0185","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/1556-276X-9-434","article-title":"In vitro performance of lipid-PLGA hybrid nanoparticles as an antigen delivery system: lipid composition matters","volume":"9","author":"Hu","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2025.114294_bb0190","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/B978-0-12-420118-7.00014-7","article-title":"New directions in nicotine vaccine design and use","volume":"69","author":"Pentel","year":"2014","journal-title":"Adv. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114294_bb0195","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.4049\/jimmunol.1500385","article-title":"The frequency of naive and early-activated Hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse","volume":"194","author":"Laudenbach","year":"2015","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3128","article-title":"Molecular programming of B cell memory","volume":"12","author":"McHeyzer-Williams","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"6146","key":"10.1016\/j.jconrel.2025.114294_bb0205","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1126\/science.1241680","article-title":"T follicular helper cell dynamics in germinal centers","volume":"341","author":"Shulman","year":"2013","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.jconrel.2025.114294_bb0210","doi-asserted-by":"crossref","first-page":"27972","DOI":"10.1021\/acsami.1c07049","article-title":"Formulation of Nanovaccines toward an extended immunity against nicotine","volume":"13","author":"Hu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.114294_bb0215","author":"Targeting"},{"key":"10.1016\/j.jconrel.2025.114294_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122758","article-title":"The immunological and pharmacokinetic evaluation of lipid-PLGA hybrid nanoparticle-based oxycodone vaccines","volume":"313","author":"Walter","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114294_bb0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41541-023-00759-y","article-title":"Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen","volume":"8","author":"Doss-Gollin","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2025.114294_bb0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejpb.2019.04.007","article-title":"Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: a kinetic study","volume":"139","author":"Thauvin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-023-00694-y","article-title":"A lipidated TLR7\/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice","volume":"8","author":"Miller","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2025.114294_bb0240","doi-asserted-by":"crossref","unstructured":"Frega G, Wu Q, Le Naour J, et al. Trial Watch: experimental TLR7\/TLR8 agonists for oncological indications. Oncoimmunology. 9(1):1796002. doi:https:\/\/doi.org\/10.1080\/2162402X.2020.1796002.","DOI":"10.1080\/2162402X.2020.1796002"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2007.02.025","article-title":"Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies","volume":"47","author":"Pockros","year":"2007","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.114294_bb0250","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/AAC.47.12.3846-3852.2003","article-title":"Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults","volume":"47","author":"Sauder","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2025.114294_bb0255","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jconrel.2014.06.027","article-title":"Designing and building the next generation of improved vaccine adjuvants","volume":"190","author":"Brito","year":"2014","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1203\/01.pdr.0000228319.10481.ea","article-title":"Innate immunity of the human newborn is polarized toward a high ratio of IL-6\/TNF-alpha production in vitro and in vivo","volume":"60","author":"Angelone","year":"2006","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114294_bb0265","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.4049\/jimmunol.167.4.2004","article-title":"The source of early IFN-gamma that plays a role in Th1 priming","volume":"167","author":"Das","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114294_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017364","article-title":"Interferon-\u03b1-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12","volume":"6","author":"Santini","year":"2011","journal-title":"PLoS One"},{"issue":"2015","key":"10.1016\/j.jconrel.2025.114294_bb0275","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The Immunobiology of Interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.jconrel.2025.114294_bb0280","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.jconrel.2025.114294_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071057","article-title":"A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA","volume":"8","author":"Coch","year":"2013","journal-title":"PLoS One"},{"issue":"7198","key":"10.1016\/j.jconrel.2025.114294_bb0290","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.jconrel.2025.114294_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2239","article-title":"Engineering kinetics of TLR7\/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation","volume":"9","author":"Bhagchandani","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.114294_bb0305","first-page":"14","article-title":"Imidazoquinolines with improved pharmacokinetic properties induce a high IFN\u03b1 to TNF\u03b1 ratio in vitro and in vivo","author":"Keppler","year":"2023","journal-title":"Front. Immunol."},{"issue":"4067","key":"10.1016\/j.jconrel.2025.114294_bb0310","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.178.4067.1290","article-title":"Evidence for active immunity to morphine in mice","volume":"178","author":"Berkowitz","year":"1972","journal-title":"Science"},{"issue":"5485","key":"10.1016\/j.jconrel.2025.114294_bb0315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114294_bb0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2011.281","article-title":"Vaccines for drug abuse","volume":"91","author":"Shen","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114294_bb0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114294_bb0330","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2025.114294_bb0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.08.009","article-title":"Lymph node targeting strategies to improve vaccination efficacy","volume":"267","author":"Jiang","year":"2017","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114294_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav6322","article-title":"Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4+ T cell activation and HIV-1 latency reversal","volume":"5","author":"Cao","year":"2019","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114294_bb0345","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.114294_bb0350","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2020.06.019","article-title":"Controlling timing and location in vaccines","volume":"158","author":"Irvine","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2025.114294_bb0355","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.nano.2018.06.005","article-title":"Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells","volume":"14","author":"Cao","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.114294_bb0360","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biomaterials.2017.05.031","article-title":"Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: a focus on hapten localization","volume":"138","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114294_bb0365","article-title":"Alum as an adjuvant for nanoparticle based vaccines: a case study with a hybrid nanoparticle-based nicotine vaccine","volume":"20","author":"Hu","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.114294_bb0370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.biomaterials.2017.11.021","article-title":"Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction","volume":"155","author":"Zhao","year":"2018","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.jconrel.2025.114294_bb0375","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1021\/acs.bioconjchem.3c00347","article-title":"Self-Adjuvanting TLR7\/8 agonist and fentanyl Hapten co-conjugate achieves enhanced protection against fentanyl challenge","volume":"34","author":"Powers","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114294_bb0380","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/10915818251355948","article-title":"Safety and toxicological evaluation of subunit keyhole limpet Hemocyanin-loaded lipid-PLGA hybrid nanoparticles (sKLH-hNPs) as a nanocarrier for an opioid use disorder vaccine","volume":"44","author":"Walter","year":"2025","journal-title":"Int. J. Toxicol."}],"updated-by":[{"DOI":"10.1016\/j.jconrel.2025.114381","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000}}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:00:24Z","timestamp":1769868024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":73,"alternative-id":["S0168365925009071"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114294","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate immune mechanisms underlying the efficacy of a next-generation nanoparticle-based vaccine against opioid use disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114294"}}